TG Therapeutics Inc. (NASDAQ:TGTX) is a fully integrated biopharmaceutical company dedicated to developing and delivering transformative therapies for patients with B-cell diseases, particularly in oncology and autoimmune disorders. Founded in 1993 and headquartered in New York, the company has built its reputation on advancing innovative treatments designed to improve patient outcomes in diseases where limited options have historically existed. Over the years, TG Therapeutics has transitioned from a development-stage biotech into a commercial-stage player with an expanding portfolio anchored by Briumvi, its FDA-approved therapy for multiple sclerosis.
At the core of TG Therapeutics’ mission is its relentless pursuit of better therapies through targeted research, rigorous clinical development, and a commitment to addressing unmet medical needs. The company initially focused on therapies for hematologic malignancies, advancing monoclonal antibodies and small molecules that aimed to reshape treatment paradigms for B-cell cancers. While it achieved important milestones in that arena, its greatest breakthrough came with the approval of Briumvi (ublituximab-xiyl) in late 2022, which positioned the company as a significant contender in the competitive multiple sclerosis market.
Briumvi quickly established itself as a differentiated therapy due to its rapid infusion times, cost-effectiveness, and strong clinical data demonstrating meaningful reductions in relapse rates and disease progression for patients with relapsing forms of multiple sclerosis. These advantages allowed TG Therapeutics to carve out market share against entrenched competitors such as Roche’s Ocrevus and Novartis’ Kesimpta. Analysts now expect Briumvi to achieve blockbuster status, with sales potentially surpassing $1 billion annually by 2027, marking a major inflection point in the company’s evolution.
Beyond Briumvi, TG Therapeutics continues to invest in pipeline expansion to sustain long-term growth and diversify its revenue base. The company is advancing a subcutaneous formulation of Briumvi that could offer patients greater convenience and compete more directly with at-home therapies. In addition, TG is actively pursuing development in cellular therapies through its Azer-cel CAR-T program targeting B-cell cancers, while also exploring applications in autoimmune disease. These efforts underscore the company’s strategy of building a broad, innovative pipeline that leverages its deep expertise in B-cell biology.
Financially, TG Therapeutics has demonstrated significant progress, shifting toward profitability as Briumvi sales accelerate and operational efficiencies take hold. The company ended 2024 with a strong cash position and manageable debt, providing flexibility to fund R&D initiatives and commercial expansion. Institutional investors and Wall Street analysts have shown increasing confidence in the company, citing its strong growth potential, attractive valuation relative to peers, and multiple upcoming catalysts that could unlock further shareholder value.
With a clear focus on innovation, patient impact, and disciplined financial management, TG Therapeutics has transformed into one of the most dynamic biotech companies in the industry. Its journey from a development-focused biotech into a commercial force with a flagship therapy, a promising pipeline, and growing institutional backing highlights the strength of its long-term vision. For investors and patients alike, TG Therapeutics represents a company at the forefront of advancing next-generation therapies that have the potential to redefine standards of care in both neurology and oncology.
TG Therapeutics at a Turning Point
TG Therapeutics, Inc. (NASDAQ: TGTX) has emerged as one of the most closely watched biotech companies in recent years, primarily due to the rapid rise of its flagship multiple sclerosis therapy, Briumvi (ublituximab). Despite volatility in share price and investor sentiment, the company remains firmly on the path to blockbuster drug status, with revenue projections that could surpass $1 billion annually by 2027. Investors are now weighing whether the softer sales growth over the last two quarters represents a temporary slowdown or a strategic buying opportunity before the next wave of catalysts takes hold. With potential stimuli on the horizon—including a consolidated dosing regime, a planned television advertising campaign, and the advancement of its pipeline—TG Therapeutics may be entering a critical inflection point.
CHECK THIS OUT: Exact Sciences (EXAS) Just Made Cancer Detection 100x Easier! and Soleno Therapeutics (SLNO): The Biotech Company That Could Make You Rich.
Briumvi Sales Growth and Market Traction
Briumvi was launched in late 2022 as a next-generation CD20-directed monoclonal antibody designed for relapsing forms of multiple sclerosis. It has quickly gained traction due to its shorter infusion times, competitive pricing, and encouraging efficacy data. In 2024, the drug generated over $400 million in revenue, and Q2 2025 sales reached $138.8 million, exceeding consensus expectations. However, Seeking Alpha reports note that the past two quarters showed relatively softer sequential growth, which partially fueled a sell-off in TGTX stock during mid-2025.
Despite this short-term moderation, analysts remain confident that Briumvi’s trajectory is intact. A consolidated dosing regime is under development, aimed at making treatment even more convenient for patients and prescribers. Moreover, a large-scale television advertising campaign could dramatically boost awareness and uptake in the coming quarters, expanding Briumvi’s market penetration against rivals like Roche’s Ocrevus and Novartis’s Kesimpta.
Clinical Strength and Long-Term Data
The bullish case for TG Therapeutics rests not just on sales momentum but also on long-term clinical durability. Five-year follow-up data demonstrated that 92% of Briumvi-treated patients avoided disability progression, while relapse rates dropped to just 0.02 annually—figures that underscore the therapy’s strength in improving quality of life for MS patients. This real-world validation strengthens payer confidence and enhances the drug’s ability to capture more of the multibillion-dollar MS market.
Pipeline Expansion: Subcutaneous Briumvi and CAR-T Therapy
TG Therapeutics is not relying solely on its current intravenous formulation. The company is advancing subcutaneous Briumvi in pivotal studies, a potential game-changer for patient adherence. If approved, this version would compete more directly with Kesimpta, which already benefits from at-home dosing convenience. A regulatory filing could come as early as 2025, creating a new catalyst for revenue acceleration.
In parallel, TG is also moving forward with its Azer-cel CAR-T program for B-cell malignancies and exploring applications in multiple sclerosis. Although still early-stage, the CAR-T program represents a high-risk, high-reward pipeline opportunity that could dramatically broaden the company’s growth profile. Investors should watch closely for competitor readouts at conferences later in 2025, which may set benchmarks for Azer-cel’s potential positioning.
Financial Health and Institutional Support
TG Therapeutics has strengthened its balance sheet, ending mid-2025 with nearly $200 million in cash and manageable debt obligations of about $111 million. Importantly, the company turned profitable in 2024 with $12.7 million in net income, proving that it is capable of sustaining operations while simultaneously investing in research and commercial expansion.
Institutional confidence remains strong, with heavyweight funds like Goldman Sachs and Wellington Management increasing their stakes. This level of backing not only validates TG’s long-term outlook but also provides liquidity support that cushions the stock against downside volatility.
Analyst Price Targets and Valuation Upside
Wall Street remains largely bullish on TG Therapeutics. Consensus price targets cluster around $40 to $46 per share, implying 35–55% upside from recent levels. Some estimates extend even higher, to $53 per share, particularly if Briumvi maintains momentum and subcutaneous approval materializes. B. Riley recently boosted its Q4 2025 EPS estimate from $0.34 to $0.36 and raised long-term EPS forecasts to over $4.40 by 2029.
While the stock does trade at a premium relative to biotech peers—its price-to-sales ratio sits above industry averages—the premium is justified by Briumvi’s unique competitive edge, blockbuster potential, and the optionality of its pipeline.
Technical Setup and Market Recognition
From a technical perspective, TG Therapeutics is also showing signs of strength. Investor’s Business Daily ranks TGTX among the top 3% of all stocks with a Composite Rating of 97. It has an EPS rating of 81, signaling strong fundamental growth. The stock is trading just above a consolidation buy point of $36.84, which suggests a technical setup that could provide a springboard for the next leg higher if catalysts align.
Potential Catalysts on the Horizon
Looking ahead, investors should monitor several key catalysts that could serve as turning points:
- Television marketing campaign launch for Briumvi in late 2025, expected to expand patient adoption.
- Regulatory submission for subcutaneous Briumvi in 2025, which could open an entirely new channel of growth.
- CAR-T trial readouts in MS and B-cell cancers, which could transform TG’s reputation from a single-product company to a multi-platform biotech.
- Earnings beats and upward guidance revisions, particularly if sequential growth accelerates again in 2026.
Risks to Monitor
Of course, the bullish thesis is not without risks. The most pressing concern is TG’s reliance on Briumvi, which currently drives nearly all revenue. Competitive threats from entrenched players like Ocrevus and Kesimpta could limit market share gains, while payer pushback remains a constant challenge in specialty medicine. Additionally, the CAR-T program, while exciting, carries significant execution and regulatory risks. Valuation is another consideration, as the stock already reflects high expectations relative to peers.
Conclusion: A High-Growth Biotech Positioned for the Next Phase
Despite two quarters of softer growth, TG Therapeutics remains a compelling growth story. The fundamentals of Briumvi are intact, bolstered by long-term data, upcoming convenience improvements, and a soon-to-launch marketing campaign that could reignite momentum. Subcutaneous Briumvi and the Azer-cel CAR-T program provide additional layers of upside optionality, while analyst consensus and institutional support offer confidence in the trajectory.
For growth-oriented investors who can tolerate biotech volatility, TG Therapeutics represents a high-conviction opportunity. With blockbuster potential, robust catalysts, and strong financial positioning, TGTX appears poised for a turnaround that could reward patient shareholders in the years ahead.
READ ALSO: Johnson & Johnson (JNJ) can be the Next Trillion-Dollar Stock and Boston Scientific (BSX) Just Signed a $45M Deal—Here’s What It Means for Investors.
